-
Atrial Fibrillation and Heart Failure With Reduced Ejection Fraction: New Assessment of an Old Problem JACC Heart Fail. (IF 10.3) Pub Date : 2024-08-14 Emily P. Zeitler MD MHS, Amber E. Johnson MD MS MBA, Lauren B. Cooper MD MHS, Benjamin A. Steinberg MD MHS, Brian A. Houston MD
Atrial fibrillation (AF) and heart failure (HF)—specifically, heart failure with reduced ejection fraction (HFrEF)—often coexist, and each contributes to the propagation of the other. This relationship extends from the mechanistic and physiological to clinical syndromes, quality of life, and long-term cardiovascular outcomes. The risk factors for AF and HF overlap and create a critical opportunity
-
Continuum of Preshock to Classic Cardiogenic Shock in the Critical Care Cardiology Trials Network Registry JACC Heart Fail. (IF 10.3) Pub Date : 2024-07-31 Siddharth M. Patel MD MPH, David D. Berg MD MPH, Erin A. Bohula MD DPhil, Vivian M. Baird-Zars MPH, Jeong-Gun Park PhD, Christopher F. Barnett MD MPH, Lori B. Daniels MD MAS, Christopher B. Fordyce MD MHS MSc, Shahab Ghafghazi MD, Michael J. Goldfarb MD MSc, Kari Gorder MD, Younghoon Kwon MD, Evan Leibner MD PhD, Venu Menon MD, Brian J. Potter MD MSc, Rajnish Prasad MD, Michael A. Solomon MD MBA, Jeffrey
The prognostic implications of phenotypes along the preshock to cardiogenic shock (CS) continuum remain uncertain. This study sought to better characterize pre- or early shock and normotensive CS phenotypes and examine outcomes compared to those with conventional CS. The CCCTN (Critical Care Cardiology Trials Network) is a registry of contemporary cardiac intensive care units. Consecutive admissions
-
Palliative Care Utilization in Patients With Heart Failure With Preserved Ejection Fraction JACC Heart Fail. (IF 10.3) Pub Date : 2024-07-31 Shahzad Hassan MD MS, Zara Latif MD, Tracy Makuvire MD MPH, Jose Lopez MD, Sarah Godfrey MD, Anuradha Lala MD, Haider J. Warraich MD
-
Obesity and Weight Loss Strategies for Patients With Heart Failure JACC Heart Fail. (IF 10.3) Pub Date : 2024-07-31 Amanda R. Vest MBBS MPH, Philip R. Schauer MD, Jo E. Rodgers PharmD, Emily Sanderson BA MS, Courtney L. LaChute MD, Jessica Seltz MS RD, Carl J. Lavie MD, Stacy A. Mandras MD, W.H. Wilson Tang MD, Adrian daSilva-deAbreu MD MSc
Obesity is a common comorbidity among patients with heart failure with reduced ejection fraction (HFrEF) or heart failure with preserved ejection fraction (HFpEF), with the strongest pathophysiologic link of obesity being seen for HFpEF. Lifestyle measures are the cornerstone of weight loss management, but sustainability is a challenge, and there are limited efficacy data in the heart failure (HF)
-
Dynamic Risk Estimation of Adverse Events in Ambulatory LVAD Patients: A MOMENTUM 3 Analysis JACC Heart Fail. (IF 10.3) Pub Date : 2024-07-24 Palak Shah MD MS, Gabriel Sayer MD, Shashank S. Sinha MD MSc, Manreet K. Kanwar MD, Jennifer A. Cowger MD MS, Francis D. Pagani MD PhD, Aditi Nayak MD, Mandeep R. Mehra MD, Joseph C. Cleveland Jr. MD, Mitchell A. Psotka MD PhD, Ramesh Singh MD, Shashank S. Desai MD, Qianhui Lu MS, Yajing Hu PhD, Allison Connolly PhD, Robert L. Kormos MD, Nir Uriel MD
Hemocompatibility-related adverse events affect patients after left ventricular assist device (LVAD) implantation but are hard to predict. Dynamic risk modeling with a multistate model can predict risk of gastrointestinal bleeding (GIB), stroke, or death in ambulatory patients. This was a secondary analysis of the MOMENTUM 3 (Multicenter Study of MagLev Technology in Patients Undergoing Mechanical
-
Coronary Revascularization in Ischemic Systolic Heart Failure: Focusing on Quality of Life, Not Quantity JACC Heart Fail. (IF 10.3) Pub Date : 2024-07-17 Yousif Ahmad PhD
-
Rapid Uptitration of Guideline-Directed Medical Therapy Regardless of Risk: It’s Not MAGGIC, It’s Science JACC Heart Fail. (IF 10.3) Pub Date : 2024-07-17 Jennifer T. Thibodeau MD MSCS, Michael M. Givertz MD
-
No Matter the Breakdown, Heart Failure Is Costly: Heart Failure Costs and Cost-Offsets by Subtype JACC Heart Fail. (IF 10.3) Pub Date : 2024-07-17 Laura P. Cohen MD MPP, James L. Januzzi MD
-
NT-proBNP: Lower Is Always Better—Even in HFpEF JACC Heart Fail. (IF 10.3) Pub Date : 2024-07-17 Antoni Bayes-Genis MD PhD
-
We Must Change Our Approach to Decongestion in Acute Heart Failure JACC Heart Fail. (IF 10.3) Pub Date : 2024-07-17 Jonathan Howlett MD, Anique Ducharme MD MSc
-
Bridging the Gap: Persistent Sex- and Race-Based Disparities in the HeartMate 3 Era JACC Heart Fail. (IF 10.3) Pub Date : 2024-07-10 Rebecca Cogswell MD, Bhavadharini Ramu MD
-
Decongestion Strategies for Ambulatory Outpatients: The Proof Is in the Urine JACC Heart Fail. (IF 10.3) Pub Date : 2024-07-10 Paula Rambarat MD, G. Michael Felker MD MHS
-
Sodium-Glucose Cotransporter Inhibitors in Heart Failure: Access, Economics, and Clinical Promise JACC Heart Fail. (IF 10.3) Pub Date : 2024-07-03 Alexander T. Sandhu MD MS, Jimmy Zheng MD MS
-
Considerations in the Diagnosis and Management of Pulmonary Hypertension Associated With Left Heart Disease JACC Heart Fail. (IF 10.3) Pub Date : 2024-07-03 Onyedika J. Ilonze MD MPH, Imo A. Ebong MD MS, Maya Guglin MD PhD, Ajith Nair MD, Jonathan Rich MD, Vallerie McLaughlin MD, Ryan J. Tedford MD, Sula Mazimba MD MPH
Pulmonary hypertension associated with left heart disease (PH-LHD) remains the most common cause of pulmonary hypertension globally. Etiologies include heart failure with reduced and preserved ejection fraction and left-sided valvular heart diseases. Despite the increasing prevalence of PH-LHD, there remains a paucity of knowledge about the hemodynamic definition, diagnosis, treatment modalities, and
-
Insights and Queries on Donor ECG's Role in Heart Transplants. JACC Heart Fail. (IF 10.3) Pub Date : 2024-07-01 Arif Albulushi,Amna Al-Busaidi
-
Treatment of Obesity in Heart Failure: The New Era in the Aftermath of the STEP-HFpEF and SELECT Trials. JACC Heart Fail. (IF 10.3) Pub Date : 2024-07-01 Biykem Bozkurt
-
Curing Ourselves of Toxic Positivity for Hospital-at-Home. JACC Heart Fail. (IF 10.3) Pub Date : 2024-07-01 Sachin H Jain
-
Toward Equitable Heart Transplant Outcomes: Interrupting Danger Signals to Define New Therapeutic Strategies. JACC Heart Fail. (IF 10.3) Pub Date : 2024-07-01 Hannah A Valantine,Kiran K Khush
-
The Path Toward a More Equitable Transplant System: There Can Be No Improvement Without Measurement. JACC Heart Fail. (IF 10.3) Pub Date : 2024-07-01 Sean P Pinney,Mary Norine Walsh
-
Inflammation and Cardiorespiratory Fitness in HFpEF: A Decade of Progress. JACC Heart Fail. (IF 10.3) Pub Date : 2024-07-01 Salvatore Carbone,Antonio Abbate
-
Reply: Insights and Queries on Donor ECG's Role in Heart Transplants. JACC Heart Fail. (IF 10.3) Pub Date : 2024-07-01 Natalie Tapaskar,Brian Wayda,Yingjie Weng,Kiran K Khush
-
Looking Under the Hood of the "Good" Cholesterol. JACC Heart Fail. (IF 10.3) Pub Date : 2024-07-01 Brendan M Everett,Amanda R O Siqueira
-
Practical Guidance for Hemodynamic Assessment by Right Heart Catheterization in Management of Heart Failure. JACC Heart Fail. (IF 10.3) Pub Date : 2024-07-01 Navin Rajagopalan,Barry A Borlaug,Alison L Bailey,Peter M Eckman,Maya Guglin,Shelley Hall,Matthew Montgomery,Gautam Ramani,Prateeti Khazanie
Heart failure is a clinical syndrome characterized by the inability of the heart to meet the circulatory demands of the body without requiring an increase in intracardiac pressures at rest or with exertion. Hemodynamic parameters can be measured via right heart catheterization, which has an integral role in the full spectrum of heart failure: from ambulatory patients to those in cardiogenic shock,
-
GDMT Initiation: Only the First Step to Getting With the Guidelines JACC Heart Fail. (IF 10.3) Pub Date : 2024-06-26 Orly Vardeny PharmD MS, Gad Cotter MD
-
Prevalence and Implications of Heart Failure Stages A-D Among Patients With Chronic Kidney Disease JACC Heart Fail. (IF 10.3) Pub Date : 2024-06-26 Amalie Johanne Lauridsen MB, Nino Emanuel Landler MD PhD, Flemming Javier Olsen MD PhD, Jacob Christensen MB, Mats Christian Højbjerg Lassen MD, Niklas Dyrby Johansen MD, Kristoffer Grundtvig Skaarup MD, Christina Christoffersen MD PhD DMSC, Ellen Linnea Freese Ballegaard MD, Ida Maria Hjelm Sørensen MD PhD, Sasha Saurbrey Bjergfelt MD, Susanne Bro MD PhD DMSC, Bo Feldt-Rasmussen MD DMSC, Ditte Hansen
-
2-Year Outcomes of an Atrial Shunt Device in HFpEF/HFmrEF: Results From REDUCE LAP-HF II JACC Heart Fail. (IF 10.3) Pub Date : 2024-06-26 Finn Gustafsson MD PhD, Mark C. Petrie MD, Jan Komtebedde DVM, Vijendra Swarup MD, Sebastian Winkler MD, Gerd Hasenfuß MD PhD, Barry A. Borlaug MD, Rajeev C. Mohan MD, James D. Flaherty MD, Aaron L. Sverdlov MBBS PhD, Peter S. Fail MD, Eugene S. Chung MD, Philipp Lurz MD PhD, Scott Lilly MD, David M. Kaye MD PhD, John G.F. Cleland MD, Maja Cikes MD, Martin B. Leon MD, Donald E. Cutlip MD, Dirk J. van
The REDUCE LAP-HF II (Reduce Elevated Left Atrial Pressure in Patients With Heart Failure II) trial found that, compared with a sham procedure, the Corvia Atrial Shunt did not improve outcomes in heart failure with preserved or mildly reduced ejection fraction. However, after 12-month follow-up, “responders” (peak-exercise pulmonary vascular resistance <1.74 WU and absence of a cardiac rhythm management
-
Distinct Comorbidity Clusters in Patients With Acute Heart Failure: Data From RELAX-AHF-2. JACC Heart Fail. (IF 10.3) Pub Date : 2024-06-24 Karla Arevalo Gomez,Jasper Tromp,Sylwia M Figarska,Iris E Beldhuis,Gad Cotter,Beth A Davison,G Michael Felker,Claudio Gimpelewicz,Barry H Greenberg,Carolyn S P Lam,Adriaan A Voors,Marco Metra,John R Teerlink,Peter van der Meer
BACKGROUND Multimorbidity frequently occurs in patients with acute heart failure (AHF). The co-occurrence of comorbidities often follows specific patterns. OBJECTIVES This study investigated multimorbidity subtypes and their associations with clinical outcomes. METHODS From the prospective RELAX-AHF-2 (Relaxin for the Treatment of Acute Heart Failure-2) trial, 6,545 patients (26% with HF with preserved
-
Optimizing Triage of Ambulatory Patients With Advanced Heart Failure: 2-Year Outcomes From REVIVAL. JACC Heart Fail. (IF 10.3) Pub Date : 2024-06-20 Keith D Aaronson,Garrick C Stewart,Lynne W Stevenson,Blair Richards,Shokoufeh Khalatbari,Thomas C Cascino,Amrut V Ambardekar,Josef Stehlik,Anuradha Lala,Michelle M Kittleson,Maryse Palardy,Maria M Mountis,Francis D Pagani,Neal Jeffries,Wendy C Taddei-Peters,Douglas L Mann,
BACKGROUND Left ventricular assist device (LVAD) use remains uncommon in advanced heart failure (HF) patients not dependent on inotropes. OBJECTIVES Before considering a randomized trial comparing a strategy of earlier use of LVAD to continued medical therapy, a better understanding is needed of the clinical trajectory of ambulatory patients with advanced systolic HF on optimal guideline-directed medical
-
Incidence and Prediction of Anoxic Brain Injury in Concomitant Cardiac Arrest and Cardiogenic Shock JACC Heart Fail. (IF 10.3) Pub Date : 2024-06-19 Lisa Besch MD, Jessica Weimann MSc, Jacob Jentzer MD, Benedikt Beer MD, Angela Dettling MD, Jonas Sundermeyer MD, Paulus Kirchhof MD, Stefan Blankenberg MD, Dirk Westermann MD, Benedikt Schrage MD PhD
-
Low Natriuretic Peptide Levels and Outcomes in Patients With Heart Failure and Preserved Ejection Fraction JACC Heart Fail. (IF 10.3) Pub Date : 2024-06-19 Toru Kondo MD PhD, Ross Campbell MBChB PhD, Pardeep S. Jhund MBChB MSc PhD, Inder S. Anand MD Dphil, Peter E. Carson MD, Carolyn S.P. Lam MBBS PhD, Sanjiv J. Shah MD, Muthiah Vaduganathan MD MPH, Faiez Zannad MD PhD, Michael R. Zile MD, Scott D. Solomon MD, John J.V. McMurray MD
Although some patients with heart failure (HF) with mildly reduced/preserved ejection fraction have low natriuretic peptide levels, there are no large-scale systematic studies of how common these individuals are or what happens to them. The purpose of this study was to examine the proportion of patients in the I-PRESERVE (Irbesartan in Heart Failure with Preserved Ejection Fraction) trial with an N-terminal
-
Combining Loop and Thiazide Diuretics Across the Left Ventricular Ejection Fraction Spectrum: The CLOROTIC Trial. JACC Heart Fail. (IF 10.3) Pub Date : 2024-06-13 Marta Sánchez-Marteles,Vanesa Garcés-Horna,José Luís Morales-Rull,Jesús Casado,Margarita Carrera-Izquierdo,Alicia Conde-Martel,Melitón Francisco Dávila-Ramos,Pau Llácer,Prado Salamanca-Bautista,Raúl Ruiz,Oscar Aramburu-Bodas,Francesc Formiga,Luís Manzano,Joan Carles Trullàs
BACKGROUND The addition of hydrochlorothiazide (HCTZ) to furosemide in the CLOROTIC (Combining Loop with Thiazide Diuretics for Decompensated Heart Failure) trial improved the diuretic response in patients with acute heart failure (AHF). OBJECTIVES This work aimed to evaluate if these results differ across the spectrum of left ventricular ejection fraction (LVEF). METHODS This post hoc analysis of
-
Cost-Effectiveness of Sotagliflozin in SOLOIST-WHF JACC Heart Fail. (IF 10.3) Pub Date : 2024-06-12 William S. Weintraub MD, Paul Kolm PhD, Sarahfaye Dolman MPH, Maria Alva PhD, Deepak L. Bhatt MD MPH MBA, Zugui Zhang PhD
The efficacy of sotagliflozin in patients with diabetes and recent worsening of heart failure was shown in the SOLOIST-WHF trial. However, the cost-effectiveness of sotagliflozin in these patients has not been previously investigated. The authors sought to determine the cost-effectiveness of sotagliflozin in patients with diabetes and recent worsening of heart failure. Based on SOLOIST-WHF trial data
-
Where Are We With Treatment and Prevention of Heart Failure in Patients Post–Myocardial Infarction? JACC Heart Fail. (IF 10.3) Pub Date : 2024-06-12 Jaclyn Carberry MB ChB, Guillaume Marquis-Gravel MD MSc, Eileen O’Meara MD, Kieran F. Docherty MB ChB (Hons) PhD
-
Representation Matters: From Clinical Trials to Early Adoption of Device Therapies JACC Heart Fail. (IF 10.3) Pub Date : 2024-06-12 Andrew J. Sauer MD
-
The March Toward Improved Heart Failure Outcomes Requires an Emphasis on Affordability JACC Heart Fail. (IF 10.3) Pub Date : 2024-06-12 Julia H.A. Foote MD, Dhruv S. Kazi MD MSc MS
-
Vericiguat and Cardiovascular Outcomes in Heart Failure by Baseline Diabetes Status: Insights From the VICTORIA Trial. JACC Heart Fail. (IF 10.3) Pub Date : 2024-06-11 Muhammad Shahzeb Khan,Javed Butler,Rebecca Young,Basil S Lewis,Jorge Escobedo,Jens Refsgaard,Eugene Reyes,Lothar Roessig,Robert O Blaustein,Carolyn S P Lam,Adriaan A Voors,Piotr Ponikowski,Kevin J Anstrom,Paul W Armstrong,
BACKGROUND Type 2 diabetes mellitus (T2DM) significantly worsens heart failure (HF) prognosis. OBJECTIVES This study sought to investigate the impact of T2DM on outcomes in patients enrolled in VICTORIA and assess the efficacy of vericiguat in patients with and without T2DM. METHODS Patients with HF with reduced ejection fraction were randomized to receive vericiguat or placebo in addition to standard
-
Randomized Trial of Cholesterol Lowering With Evolocumab for Cardiac Allograft Vasculopathy in Heart Transplant Recipients. JACC Heart Fail. (IF 10.3) Pub Date : 2024-06-10 Kaspar Broch,Karl B Lemström,Finn Gustafsson,Hans Eiskjær,Kristjan Karason,Grunde Gjesdal,Morten W Fagerland,Markku Pentikainen,Jyri Lommi,Einar Gude,Arne K Andreassen,Tor S Clemmensen,Evald H Christiansen,Elisabeth Bjørkelund,Erlend S Berg,Satish Arora,Lars Gullestad
BACKGROUND Cardiac allograft vasculopathy is characterized by increased coronary intimal thickness and is a leading cause of death in heart transplant (HTx) recipients despite the routine use of statins. The experience with inhibitors of proprotein convertase subtilisin-kexin type 9 in HTx recipients is limited. Our hypothesis was that lowering cholesterol with the proprotein convertase subtilisin-kexin
-
Therapeutic Options in Ambulatory Advanced Heart Failure: A Moving Target. JACC Heart Fail. (IF 10.3) Pub Date : 2024-06-06 Shannon M Dunlay,Thomas C Hanff,Stavros G Drakos
-
Novel Initiative Increasing GDMT Use Among Patients With Heart Failure With Reduced Ejection Fraction JACC Heart Fail. (IF 10.3) Pub Date : 2024-06-05 Andrei Minciunescu MD, Carolyn Rosner MSN NP-C MBA, David Kepplinger PhD, Therese Del Castillo BSN RN, Deanna Overbeck RN, Warren S. Levy MD, Christopher M. O’Connor MD, Tariq M. Haddad MD
-
Obesity, Challenges, and Weight-Loss Strategies for Patients With Ventricular Assist Devices. JACC Heart Fail. (IF 10.3) Pub Date : 2024-06-03 Adrian daSilva-deAbreu,Jo E Rodgers,Jessica Seltz,Stacy A Mandras,Carl J Lavie,Juan Francisco Loro-Ferrer,Hector O Ventura,Philip R Schauer,Amanda R Vest
For adults with advanced heart failure, class II/III obesity (body mass index ≥35 kg/m2) represents major challenges, and it is even considered a contraindication for heart transplantation (HT) at many centers. This has led to growing interest in preventing and treating obesity to help patients with advanced heart failure become HT candidates. Among all weight-loss strategies, bariatric surgery (BSx)
-
Screening for Unrecognized HFpEF in Atrial Fibrillation and for Unrecognized Atrial Fibrillation in HFpEF. JACC Heart Fail. (IF 10.3) Pub Date : 2024-06-01 Yogesh N V Reddy,Peter Noseworthy,Barry A Borlaug,Nancy M Albert
Because of the bidirectional relationship between atrial fibrillation (AF) and heart failure with preserved ejection fraction (HFpEF), individuals with either condition require consideration of screening for the other. In this review, we summarize current evidence and rationale for screening for occult HFpEF in adults with clinical AF; and occult AF in patients with clinically recognized HFpEF. Assessment
-
Asymmetric Dimethylarginine in Pulmonary Arterial Hypertension: A Liquid Biopsy to Assess Pulmonary Vascular Endothelial Health. JACC Heart Fail. (IF 10.3) Pub Date : 2024-06-01 Thenappan Thenappan
-
Reply: Middle-Aged Children With Heart Failure. JACC Heart Fail. (IF 10.3) Pub Date : 2024-06-01 Fen Yang,Imre Janszky,Jiong Li,Krisztina D László
-
Illuminating a Hidden Risk: The Genetic Contribution to Acute Myocarditis. JACC Heart Fail. (IF 10.3) Pub Date : 2024-06-01 Enrico Ammirati,Amy R Kontorovich,Leslie T Cooper
-
The Link Between Heart Failure and Neurodegeneration: Insights From Circulating Biomarkers. JACC Heart Fail. (IF 10.3) Pub Date : 2024-06-01 Jan Traub,Kieran F Docherty,Anna Frey
-
Hard Work and Talent in the Battle Against Heart Failure. JACC Heart Fail. (IF 10.3) Pub Date : 2024-06-01 David A Baran,David Snipelisky
-
Serum Markers of Neurodegeneration Are Strongly Linked to Heart Failure Severity and Outcome. JACC Heart Fail. (IF 10.3) Pub Date : 2024-06-01 Raphael Wurm,Suriya Prausmüller,Markus Ponleitner,Georg Spinka,Annika Weidenhammer,Henrike Arfsten,Gregor Heitzinger,Noel Gilian Panagiotides,Guido Strunk,Philipp Bartko,Georg Goliasch,Elisabeth Stögmann,Christian Hengstenberg,Martin Hülsmann,Noemi Pavo
BACKGROUND Cognitive impairment is prevalent in patients with heart failure with reduced ejection fraction (HFrEF), affecting self-care and outcomes. Novel blood-based biomarkers have emerged as potential diagnostic tools for neurodegeneration. OBJECTIVES This study aimed to assess neurodegeneration in HFrEF by measuring neurofilament light chain (NfL), total tau (t-tau), amyloid beta 40 (Aβ40), and
-
Medicare's Canopy to the Roots of Heart Failure Management: Seeing the Trees or the Forest? JACC Heart Fail. (IF 10.3) Pub Date : 2024-06-01 Melvin R Echols,Dipti Itchhaporia,Paul Douglass
-
The Year in Review in Heart Failure. JACC Heart Fail. (IF 10.3) Pub Date : 2024-06-01 Biykem Bozkurt
-
Pulse Pressure Response to Inotrope Therapy in Cardiogenic Shock: A Subanalysis of the DOREMI Trial. JACC Heart Fail. (IF 10.3) Pub Date : 2024-06-01 Jiho Han,Pietro Di Santo,Rebecca Mathew,Benjamin Hibbert,Jonathan Grinstein,Mark N Belkin
-
Use of Digital Devices in Patients With Heart Failure. JACC Heart Fail. (IF 10.3) Pub Date : 2024-06-01 Orhun Kose,George Perlman,Abhinav Sharma
-
Heart Failure With Preserved Ejection Fraction in Patients With Atrial Fibrillation: Hidden in Plain Sight. JACC Heart Fail. (IF 10.3) Pub Date : 2024-06-01 Rosita Zakeri,Selma F Mohammed
-
From Mechanisms to Phenotypes: Metabolomic Profiling of Patients Receiving Dapagliflozin in DEFINE-HF and PRESERVED-HF. JACC Heart Fail. (IF 10.3) Pub Date : 2024-06-01 Amanda R Vest,Patrick M Hyland
-
Managing Patients on SGLT2 Inhibitors in Primary Care. JACC Heart Fail. (IF 10.3) Pub Date : 2024-06-01 Javed Butler,John E Anderson
In this video, Javed Butler, MD, and John E. Anderson, MD, discuss the management of patients on SGLT2 inhibitors in the primary care setting.
-
Use of SGLT2 Inhibitors in Patients With HF With and Without Type 2 Diabetes: An Endocrinologist's Perspective. JACC Heart Fail. (IF 10.3) Pub Date : 2024-06-01 Javed Butler,Rachel Pessah-Pollack
In this video, Javed Butler, MD, and Rachel Pessah-Pollack, MD, discuss the use of SGLT2 inhibitors in patients with and without type 2 diabetes.
-
Epidemiology of Heart Failure and the Discovery of the Cardioprotective Effects of SGLT2 Inhibitors. JACC Heart Fail. (IF 10.3) Pub Date : 2024-06-01 Javed Butler,Jonathan Rich
In this video, Javed Butler, MD, introduces the series on the use of SGLT2 inhibitors in heart failure. He discusses the epidemiology of heart failure and the effects of SGLT2 inhibitors on heart failure outcomes. Jonathan Rich, MD, joins to summarize the effects of SGLT2 inhibitors from dedicated trials in patients with heart failure.
-
Autoimmune Disorders in Heart Failure With Preserved Ejection Fraction JACC Heart Fail. (IF 10.3) Pub Date : 2024-05-29 Atsushi Tada MD PhD, Shunichi Doi MD PhD, Tomonari Harada MD PhD, Tatsuro Ibe MD PhD, Jwan A. Naser MBBS, Matthew Amdahl MD PhD, Yogesh N.V. Reddy MBBS, Barry A. Borlaug MD
-
Increasing Phosphorylated Tau Protein Serum Levels in the Course of Chronic Heart Failure JACC Heart Fail. (IF 10.3) Pub Date : 2024-05-22 Jan Traub MD, Markus Otto MD, Camelia Maria Monoranu MD, Patrick Oeckl PhD, György Homola PhD, Dejan Radaković MD, Mirko Pham MD, Stefan Störk MD PhD, Guido Stoll MD, Anna Frey MD
-
Eating to Prevent Both Heart and Planetary Failure: The EAT-Lancet Diet JACC Heart Fail. (IF 10.3) Pub Date : 2024-05-22 Leah E. Cahill PhD RD, Scott L. Hummel MD MS
-
Association of High-Density Lipoprotein Parameters and Risk of Heart Failure: A Multicohort Analysis JACC Heart Fail. (IF 10.3) Pub Date : 2024-05-15 Ambarish Pandey MD MSCS, Kershaw V. Patel MD MSCS, Matthew W. Segar MD MS, Michael D. Shapiro DO MCR, Christie M. Ballantyne MD, Salim S. Virani MD PhD, Vijay Nambi MD PhD, Erin D. Michos MD MHS, Michael J. Blaha MD MPH, Khurram Nasir MD MPH MSc, Miguel Cainzos-Achirica MD MPH PhD, Colby R. Ayers MS, B. Daan Westenbrink MD PhD, Jose L. Flores-Guerrero MD MSc, Stephan J.L. Bakker MD PhD, Margery A.